Work

Real world comparison of time-to-next-treatment (TTNT), time-to-castration-resistance (TTCR), and overall survival (OS) among patients with BRCA1/2 positive and homologous recombination repair (HRR) negative metastatic castration-sensitive prostate cancer (mCSPC).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.77

Authors: Heather H. Cheng, Sabree Burbage, Carmine Rossi, Ibrahim Khilfeh, Lilian Diaz, Yuxi Wang, Dominic Pilon, Gordon Andrew Brown, Neal D. Shore, Benjamin H Lowentritt, Daniel W. Lin, Mehmet Asim Bilen

Institutions: University of Washington, Johnson & Johnson (United States), New Jersey Urology, Rowan University, Carolina Urologic Research Center, Chesapeake Urology Associates, Winship Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4407699384

Cites:

Cited by:

Related to: 10